contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


faron-pharmaceuticals-research-program-progressing-planned

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Is there any new info to be gleaned from this? BONO on LinkedIn: Breaking mmunotherapy resistance—Blaze trial to start🔥  Huge thanks to Dr. Anna Minchom for persistence. BEXMAB trial in AML and MDS has shown that bexmarilimab (BEX) is an ideal backbone for combination treatments, and now we’re moving that momentum into solid tumours. First up: the Blaze trial at The Institute of Cancer Research in partnership with The Royal Marsden, combining bexmarilimab + anti‑PD‑1 (zimberelimab) to re‑sensitize patients with metastatic NSCLC and melanoma who have progressed within 12 weeks of the last dose of immune checkpoint therapy.  This is a logical next step after the MATINS first‑in‑human study, where single‑agent bexmarilimab delivered disease control and Anna played a key role as investigator. In this BLAZE proof-of-concept study, metastatic NSCLC and melanoma patients exhibiting secondary resistance to immune checkpoint inhibitors are treated with bexmarilimab + zimberelimab.  Breaking immunotherapy resistance starts here!

Possible ≠ realistic Unrealistic ≠ impossible Yeah, an over-optimistic estimate back then for sure, but biotechs raising money usually tend to speak over-optimistically rather than too pessimistically. Even here, there’s immediate panic if there isn’t enough hype in the press release. Company management’s talk should always be taken with a grain of salt, or however that saying went. I mean, the science and numbers etc. must be true of course, but the assessment of the outlook tends to be quite heavily on the positive side.

Well, optimistic, if we want to be politically correct… to me, that rather shows that Faron hasn’t even had a realistic understanding of bex’s regulatory path to becoming a drug. As recently as early 2025, it was being suggested that accelerated approval would be possible by late 2025 (in the r/r branch). I wrote a long time ago that the AA plan is not realistic; the FDA will not approve it. Whether this remains the only stumbling block remains to be seen.

An old article caught my eye. The schedule estimates were quite optimistic a couple of years ago. The goal was to submit a marketing authorization application to the FDA in early 2025:            sttinfo.fi              Suomalainen Faron hakee syöpälääkkeelleen myyntilupaa Yhdysvaltain...    Faron Pharmaceuticals on julkaissut tänään uusia positiivisia tuloksia BEXMAB-tutkimuksesta, jossa tutkitaan yrityksen kehittämän täsmäimmunoterapian eli bexmarilimabin tehoa useisiin pahanlaatuisiin hematologisiin kasvaimiin eli verisyöpiin. Yritys...

I wonder how many patients are being recruited for this and when we’ll get the first readouts? If they already show an early positive signal, we’re onto something big.

Scientific research on bexmarilimab and Clever in a clinical setting is now moving to the next level. The contribution of Maija’s lab + the British + the Chinese labs has been important—Maija’s indispensable—but now, one of the world’s renowned cancer research institutes, the INSTITUTE FOR CANCER RESEARCH https://www.icr.ac.uk/ , is also providing support. I’m sure every bit of data will be squeezed out of the combo trial; the concern over biomarkers—i.e., whether everything Faron hopes for is available—is likely unnecessary. Costs will remain low if the research arsenal includes support from the institute and zimbe (zimberelimab) from Gilead. Royal Marsden is the investigator. Anna Minchom was the lead investigator there during MATINS as well; Bex likely stuck in her mind. According to Faron, ethical approval for BLAZE has already been obtained. Thus, the dosages and patient samples are likely already known, though they aren’t available online unless someone digs them up. Gilead’s run of bad luck continues https://www.fiercebiotech.com/biotech/arcus-halts-gilead-partnered-tigit-trials-biotech-reworks-rd-focus For a PD-1 combo with zimberelimab in solid tumors, the hope was for the immunological anti-TIGIT drug domvanalimab, but it’s going south, just like the TIGITs of other pharma companies. This was also a collaborative project with Arcus, like zimbe. There, Gilead/Arcus tried to outperform the blockbuster drug Opdivo by combining zimbe+domva with chemo in gastric and esophageal cancer. It wasn’t better, but was zimbe as good as Opdivo? TIGIT’s misfortune could be Faron’s luck. The fact that zimbe can still be considered an experimental drug is a risk. It only has approval in China, and apparently, data is still only from open-label phase 2 trials. That explains the rather blunt statement in Faron’s release: “Zimberelimab is an investigational molecule that has not received approval from any regulatory authority worldwide.” Perhaps from an FDA/EMA perspective, this is a valid statement. An honest release. Combo trials for lung cancer with zimbe are also ongoing globally in phase 3. If the Bex combo doesn’t work, Faron can blame zimbe and look for another drug proven to work in monotherapy, such as Opdivo. If the zimbe combo doesn’t work, Gilead will conclude that it’s no wonder there’s no efficacy with zimbe, since the competitor’s equivalent also failed, and will also state that adding Bex doesn’t help either. The Gilead collaboration might not continue. On the other hand, if preliminary efficacy and safety start to show, both can praise themselves and each other, and a storm warning will have been issued to the entire massive PD-1 field. The fact that Gilead could state that when the efficacy of pembro (pembrolizumab), Opdivo, etc., etc., runs out, we take over from there, would be—to put it mildly— for them and for us. There’s plenty of suspense for everyone, and that’s why we’re here

Well, the PD-1 combination study finally came out; I noticed I’ve been calling for it for nearly five years now. I feel like putting on a dunce cap since I’ve been so wrong about it—specifically regarding the timing. But better late than never, although this data really should have been available during the financing agreement negotiations to achieve the results that were previously tossed around in the bigger predictions here.

Faron Pharmaceuticals

We have updated our assessment of the progress of Faron’s research program and based on that, the commercial potential of the company's drug candidates. The individual studies of the research...

<p>We have updated our assessment of the progress of Faron’s research program and based on that, the commercial potential of the company's drug candidates. The individual studies of the research program have largely progressed as we expected and the changes to our model are moderate in size. The most important change is the increased number of blood cancer patients who could potentially benefit from bexmarilimab (BEX). However, since October, the share price has increased more than our fair value, which weakens the share’s risk/return ratio. We believe the share is close to the upper limit of its fair value range.</p> 

	2021	22e	23e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-21.1	-22.1	-0.8
EBIT-% (adj.)	-527,700.0 %	-551,975.0 %	-20,292.5 %
EPS (adj.)	-0.40	-0.37	-0.02
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Faron Pharmaceuticals: Research program progressing as planned

Key Estimate Figures2023-01-09

Forum discussions